Poster

Lead Extraction and Management

Read more about Lead Extraction and Management

Clinical effectiveness and persistence on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup

BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...

11/26/2024

Real-world clinical effectiveness of esketamine nasal spray based on the Montgomery-Asberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in the United States

BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...

11/26/2024

Response and remission on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup

BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...

11/26/2024

Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation

BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...

11/26/2024

Effect of Centanafadine on AISRS Over 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials

TBD

11/26/2024

Impact of Centanafadine on the ASRS After 6 Weeks of Treatment of ADHD in Adults: A Pooled Analysis of Two Phase 3 Trials

Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...

11/26/2024

Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia

Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...

11/26/2024

Guiding antidepressant choice by applying deep learning approaches on individual patient-derived neurons: a window to drug efficacy in each patient

Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...

11/26/2024

Patient Satisfaction with KarXT Treatment for Schizophrenia: A Qualitative Interview-Based Study

KarXT is a novel treatment that does not directly block dopamine D2 receptors. A new drug application for KarXT was recently accepted by the FDA to treat schizophrenia in adults. An impor...

11/26/2024